Education [MSc/MD/PhD neuroscience] Promotion of young researchers Flow cytometry Brain imaging [from cell to system] Proteomik,Genomik, Genetik Research area A: Mechanisms of damage Research Area B: Endogenous brain protection Research area C: Regeneration Research area D: Crosstalk between nervous and immune system Research area E: Developmental disturbances Research area F: Plasticity Disorders of network formation Neuroinflammation Cerebro-vascular diseases (CVD) Research unit for long-term outcome and behavioral analysis Research unit for long-term outcome and behavioral analysis NeuroCure Clinical Research Center

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

top


Proteomics, genomics, genetics

The Max Delbrück Center for Molecular Medicine, the Max Planck Institute for Molecular Genetics and the Leibniz Institute for Molecular Pharmacology have been und will be making available a number of genome and proteomic research technologies available, which will be instrumental in solving important medical tasks with respect to neurological disorders like stroke, multiple sclerosis, or epileptic seizures and may even reveal the cellular networks underlying the mechanisms of brain damage, brain protection, and regeneration.

 

  • Automated Y2H/Y3H screening technology for the high-throughput identification of human protein-protein interactions; Assays for the systematic validation of interactions; Y2H libraries: 12,000 human prey clones
  • Technology for the for the systematic identification of human protein interactions using protein arrays; Spotting robots for the production of protein arrays
  • Technology for the isolation and characterization of protein complexes using affinity chromatography and mass spectrometry (Q-Tof Premier; 4000 Q-Trap LC/MS/MS system)
  • Array CGH technology (BAC contig and oligonucleotide arrays)
  • Illumina Bead Station for high-throughput SNP typing (e.g. homozygosity mapping) and gene expression profiling
  • Roche 20 ('454') and Solexa sequencing systems
  • Access to large cohorts of patients and families with neurological disorders (e.g. through the Euro-MRX Consortium, our collaboration with Iran and with other partners)